Eliquis, Bydureon Launches Still A Wait-And-See Story For Bristol
This article was originally published in The Pink Sheet Daily
Executive Summary
Investors are focused on the launch of both drugs, which are expected to contribute meaningfully to Bristol’s return to growth, as well as on nivolumab, a promising anti-PD-1 in development for cancer. Few conclusions can be drawn on any of those fronts from the company’s first quarter financial update.
You may also be interested in...
Bristol-Myers Squibb And Bayer Keep The Focus On China: Emerging Markets Earnings Roundup (Part 2)
During Q1, BMS welcomed its new R&D president and also saw new products launched in China, while Bayer’s mature products reported strong growth in China.
Incoming Bristol R&D Chief Cuss Initially Plans To Follow Sigal’s Course Of Action
Long-time senior VP of R&D Francis Cuss will succeed Elliott Sigal as Bristol’s head of R&D on July 1, following a transition period. In an investor call, Cuss indicated no great change in strategy but acknowledged an ongoing need to evolve corporate thinking and capability.
Eliquis Label Looks Great, But May Leave Door Open For Pradaxa To Compete On Efficacy
Bristol/Pfizer’s Eliquis secures an attractive FDA label for atrial fibrillation on three key fronts: superior stroke prevention, reduced major bleeding and reduced all-cause mortality. With its superiority in preventing hemorrhagic strokes, Eliquis has the clear lead in terms of safety. But Boehringer’s competing Pradaxa remains the only new oral anticoagulant with proven superiority for preventing purely ischemic strokes, which is the main goal of atrial fibrillation treatment.